RxDoctor Payments Data

Sameer Sharma, MD

Gynecologic Oncology · Dyer, INNPI 1033278056

Payments from drug & device makers

What this record shows

This record is dominated by education: $24,750 of the $27,153 with a category attached, or 91.1%. Intuitive Surgical accounts for 96.3% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2021 at $17,041 and has fallen 99.2% since, to $139 in 2025. Among gynecologic oncology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$27,153in general payments, 2019–2025

Across 60 payments — averaging $452.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$26K
  • Merck$150
  • Davol Inc.$125
  • GSK$105
  • AstraZeneca$99
  • Eisai Inc.$84
  • plus $450 from 16 others

What the payments were for

  • Food & beverage$2,4039%
  • Education$24,75091%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,153 in reported general payments places this provider in the 95th percentile of 26 gynecologic oncology providers in Indiana.

See all gynecologic oncology providers in Indiana

Medicare billing

Part B allowed, 2024
$191,211
Medicare patients
391
Services billed
1,306

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg78$1,355
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl28$387

Paid to pharmacies, not to this prescriber.

Other gynecologic oncology in Dyer

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →